In honor of Breast Cancer Awareness Month, we were pleased to have the opportunity to interview Jennifer Reynolds, Founder and President of Pink Warrior Advocates, an organization dedicated to providing direct financial and emotional support to women undergoing treatment for a breast cancer diagnosis.
As a breast cancer survivor who later discovered she had a predisposed pathogenic variant, Jennifer discussed why genomic testing for hereditary cancer risk factors is critical to so many people’s health journey.
Why do you think that genomic testing for hereditary cancer matters?
Knowing that you have these hereditary cancer risk factors is powerful information. It allows you, as a patient, to move forward and take control of your health versus your health controlling you.Continue reading “Knowing that You Have Hereditary Cancer Risk Factors is Powerful Information”
COVID-19 testing has been a hot topic since the outbreak of the viral pandemic. Phrases such as “nasal swabs” and “viral genetic material” have moved from clinical vocabulary into the mainstream consciousness, and new tests arrive on the market seemingly weekly. But what do you need to consider if your doctor, employer, or school asks you to get a COVID-19 test? How do you know whether it’s the right type of test? Or, if you can trust the result?
Lab-based PCR Tests
The most common type of COVID-19 test, and the one described as the “gold standard” for its ability to detect even tiny amounts of virus accurately, is called a PCR (or polymerase chain reaction) test. With this test, a swab is taken from the nasal passage or throat by a medical professional. Some versions of the test are approved for use in asymptomatic individuals, while others are intended only for those displaying symptoms.Continue reading “COVID-19 Testing 101: Which COVID-19 Test is Right for You?”
As schools start to reopen across the country, parents have some new concerns to contend with, alongside the usual anxieties about new teachers, classmates, and choosing the right backpack. Could their child catch COVID-19 at school and fall ill? Might they bring the infection home and pass it to vulnerable family members? Will further outbreaks lead to school shutdowns and more missed learning opportunities?
The most recent research indicates that while children can contract COVID-19, their symptoms are, fortunately, usually mild. However, even mildly affected children can spread SARS-CoV-2, the virus that causes COVID-19. A study published in JAMA Pediatrics found that infected children shed (release from their body) at least as much SARS-CoV-2 virus as adults. Children also shed SARS-CoV-2 for a prolonged period, according to research published in the Journal of Pediatrics, and can simultaneously have the virus and antibodies against it (often seen as an indicator of immunity) in their system. Furthermore, an in-depth contact tracing study in South Korea concluded that school-aged children were slightly more likely to transmit the virus to family members in the home than adults.
Since fever is a common symptom of COVID-19, many workplaces and other communal spaces have attempted to minimize the spread of infection by measuring the temperatures of everyone entering their premises. Could this approach help keep COVID-19 out of our schools? Unfortunately, this kind of screening could miss many infected students since not all children with COVID-19 experience fever and infected individuals can spread the virus for days before they feel ill.
The best way to detect COVID-19 is through viral testing, as it does not rely on the identification of symptoms. However, schools currently face two significant obstacles to implementing such a strategy: speed and detection.Continue reading “How Safe is it to Go Back to School?”
For two years, Elizabeth and Michael* lived with their daughter’s diagnosis of Gaucher disease, a genetic disorder that impacts many of the body’s organs and tissues. They anxiously watched Sophie’s development through infancy into toddlerhood for early signs and symptoms. They engaged with disease advocacy organizations and patient communities, found specialists they trusted, and prepared as best they could for the financial crush of biweekly intravenous infusions that Sophie would eventually need to cope with her illness.
However, Sophie never had Gaucher disease. Her diagnosis was the result of a false positive on a lab test, caused by a nonfunctional piece of DNA called a pseudogene.
Uncovering the unexpected
When Elizabeth was pregnant with Sophie, she found out through a targeted carrier screen for people of Ashkenazi Jewish descent that she was a carrier of a relatively mild version of Gaucher disease. Carriers themselves are unaffected; it’s only when someone inherits the disease-causing variant from both parents that he or she will develop the disease. Gaucher disease affects the spleen, liver, and bone marrow and is a variable onset disease, which means symptoms may appear anytime during childhood or even early adulthood. While treatable, treatment for most people means intravenous infusions every two weeks for life. On top of the emotional and physical stress of this disease, treatment is very expensive, running into hundreds of thousands of dollars per year for a single patient – a heavy financial burden that many people cannot afford.Continue reading “How Sema4 Expanded Carrier Screening Brought A Family Relief — and Reliable Results”
Today, Sema4 scientists released results from an analysis of patients tested for SARS-CoV-2 at five hospitals in the Mount Sinai Health System. Spanning more than 28,000 patients, this is one of the largest and most racially diverse COVID-19 studies performed in the U.S. to date. The study findings were posted as a preprint on medRxiv.
Our team analyzed de-identified electronic medical records from 28,336 patients tested for SARS-CoV-2 at Mount Sinai Health System hospitals in Manhattan, Brooklyn, and Queens between February 24 and April 15. Of those patients, 6,158 tested positive for the coronavirus and 3,273 were admitted to the hospital.
Consistent with other reports, this study confirmed that COVID-19 prevalence in African Americans and Hispanics is disproportionately high in New York City. However, for patients admitted to the hospital, our analysis found no differences in mortality rates based on ethnicity, indicating that in-patient care helps to address this healthcare disparity.Continue reading “Outcomes Data Published from Large, Diverse COVID-19 Patient Study in NYC”
Expanded carrier screening provides maximal carrier identification for individuals of all Jewish backgrounds, according to a recent study, by researchers from Sema4 and the Icahn School of Medicine at Mount Sinai. Our results, published in Molecular Genetics & Genomic Medicine, showed that the majority of variants detected using an expanded panel would be missed by following subgroup-specific guidelines.
Screening for genetic disease in Jewish populations
Some genetic diseases are more common in individuals of Jewish ancestry than in the general population. There are also differences in disease frequency between Jewish subgroups. These disparities have led to subgroup-specific recommendations for what should be tested and the labeling of conditions as Ashkenazi Jewish (AJ)- or Sephardi/Mizrahi Jewish (SMJ)-specific.
Sema4’s core mission is to improve health outcomes through increased data and information. The study’s authors, headed by our Chief Diagnostics Officer, Dr. Lisa Edelmann, therefore questioned whether a subgroup-specific approach is an optimal way to detect carriers, or whether a broader approach is better. To answer this question, we set out to design a next-generation sequencing (NGS)-based targeted panel that included not only AJ and SMJ diseases but also pan-Jewish and pan-ethnic conditions.Continue reading “Sema4 Study Underscores the Importance of Expanded Carrier Screening for Individuals of Jewish Descent”
It is Women’s History Month, which celebrates the contributions of women to events in history and contemporary society. To mark the occasion, we are featuring some of our female employees at Sema4. In the fourth, and final, Q&A of this series, Kate Bogdanova, a Variant Curator on our all-female somatic variant curation team, discusses her innovative work at Sema4 and the influence of her role models. Read the previous installments of this series by clicking here, here, and here
1. What is your role at Sema4?
I am a variant scientist in the oncology curation team. Variants are changes in the DNA, some of which can increase a person’s chance of developing cancer. I act as a liaison between the Knowledge Base (KB) group and the Reporting Laboratory Directors. The KB group provides expertise on specific cancer types and guidance on which treatments may benefit the patient most based on the variants identified in their tumor’s DNA/RNA. My role is to make sure that all the relevant variants are included in the patient’s report, properly annotated and classified. We also ensure that the report itself is cohesive and scientifically correct, and that recommended trials are appropriate based on the patient’s clinical and family history.
2. What motivates you to work at Sema4?
I really appreciate our innovative approach, from the tests we offer, on both the germline and somatic sides, to the tools that we are developing to support those tests. We provide critical information to our patients and physicians and connect them to Pharma to help them get into a trial or the other way around. I take great pride in the role I play in this extensive process. Our reports may help to identify a misdiagnosis or to verify the suspected diagnosis, which will translate into better risk assessment or treatment options for our patients.Continue reading “Women’s History Month Q&A with Kate Bogdanova”
It is Women’s History Month, which celebrates the contributions of women to events in history and contemporary society. To mark the occasion, we are featuring some of our female employees at Sema4. In our third Q&A of this series, Michelle Ning, a Genetic Counselor based in our Branford lab, discusses advocating for patients and their families, and why her grandmother inspired her to be a woman of science. Read our previous installments of this series by clicking here and here.
1. What is your role at Sema4?
As a Lab Genetic Counselor (GC), I wear a lot of different hats, which makes it a particularly rewarding role. I help patients understand the genetic testing process and what it means for them and their families, while also guiding healthcare providers on what our test options are and how the results may impact their patients. I develop comprehensible educational materials, as well as consent forms. In the lab, I review hereditary cancer genetic test orders to ensure they are a good fit for the patient based on their individual and family medical history.
2. What motivates you to work at Sema4?
Sema4 cares about the patient experience. This very much aligns with my philosophy and background. I started my career in the clinic and have always advocated for patients and their families. I am proud to still be able to provide this advocacy as part of my role at Sema4.Continue reading “Women’s History Month Q&A with Michelle Ning”
It is Women’s History Month, which celebrates the contributions of women to events in history and contemporary society. To mark the occasion, we are featuring some of our female employees at Sema4. In our second Q&A of this series, Nefize Sertac Kip, Medical Director in our Branford lab, discusses what Women’s History Month means to her and why Turkan Saylan, a prominent female Turkish doctor, has inspired her. Read our first installment of this series by clicking here.
1. What is your role at Sema4?
As one of the Oncology Lab Directors, I sign out clinical reports of next generation sequencing of tumor specimens, select appropriate platforms, software, and kits to use in the laboratories and figure out which assays (an investigative procedure in laboratory medicine) to bring on board, or how to validate and apply within New York State. I review the pathology reports and tumor slides to provide the appropriate codes for downstream analysis. I manage the variant curation and annotation team that provides the gene narratives, clinical trial information, and appropriate therapies to explain the roles of the mutant genes in various tumors important in diagnosis, prognosis and therapy. I am also involved in oncology research, fellows’ training and building our histology and AI-driven digital pathology capabilities.
2. What motivates you to work at Sema4?
Sema4 is very futuristic and cutting edge. I am lucky to work with so many knowledgeable and sophisticated lab directors, genetic counselors, bioinformaticians, curators, scientists, software engineers, technicians and administrative staff. We collaborate in a multidisciplinary fashion to deliver the best possible solutions to healthcare providers and their patients.
3. What does Women’s History Month mean to you?
It means a lot. I admire Ataturk, the founder of modern Turkey, whose democratic ideals led him to emancipate women, and encouraged them to receive education in science and join the workforce with equal rights to men. In that spirit, I chose to pursue my medical training. I was following the example of other females in my family who also recognized the importance of education. Many women in my family took on leadership roles. My grandmother, though she did not work, was a very prominent figure at home. My mom, who is an entrepreneur and still working, has been instrumental in my motivation to excel as a human being and as a career-oriented female.Continue reading “Women’s History Month Q&A with Nefize Sertac Kip”